P/B
0,8
Bio Green Med Solution
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
$5.6M
Market Cap • 10/9/2026
1996
(30 years)
Founded
2006
(20 years ago)
IPO
NASDAQ
Listing Exchange
Malaysia
Country
Valuation
P/S
3
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,1
EPS
—
Market Cap
Market Cap
5,6M
EV
1,8M
EV/Revenue
1
EV/EBITDA
-0,7
EV/EBIT
-0,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-31,6%
Total Yield
-31,6%
Payout
0%
Retained Earnings
-455M
Profitability
Gross Margin
19,3%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0,1%
Capex/D&A
20%
Capex/OCF
-0,1%
SBC/OCF
—
% PPE
1,8%
% Goodwill
20%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
1,4
Debt/Equity
0%
Current Ratio
8,6
Quick Ratio
7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!